Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Assistance Publique - Hôpitaux de Paris |
---|---|
Information provided by: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT00451503 |
The middle ear implant are used for patients with mild to severe sensorineural hearing loss, who cannot benefit from conventional hearing aids because of medical reasons such as chronic external otitis or external skin irritation. The device is also available for patients who are dissatisfied with the conventional hearing aids because of poor sound quality, feedback or occlusion of the ear canal. To date, more than 1500 patients have been implanted in Europe and about more than 600 patients in France. The aim of the present study is to compare in a randomized study the performances of the system to those of the conventional hearing aid in patients with similar degree of hearing loss.
Condition | Intervention |
---|---|
Hearing Loss |
Device: Middle Ear Implant |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Evaluation of Middle Ear Implants in the Therapeutic Strategy of Auditory Rehabilitation in Case of Failure of Conventional Hearing Aid |
Estimated Enrollment: | 420 |
Study Start Date: | March 2007 |
Estimated Study Completion Date: | March 2011 |
Estimated Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
surgery
|
Device: Middle Ear Implant
surgery
|
Objective: The main objective of this study is to demonstrate that the middle ear implant increases the hearing in terms of speech intelligibility in quiet and noisy conditions, in patients who have no further benefit of their conventional hearing aid. The quality of life of these patients will be evaluated as well as the tolerance of the middle ear implant after 6 months.
Design of the study: 420 patients with mid or severe hearing loss will be included. They will have for 3 months the best conventional hearing aid adapted to their hearing loss. The first 84 patients who will not have a benefit of this hearing aid, will be randomised in two groups. The patients of the first group will be operated as soon as possible, the surgery of the patients of the second group will be delayed by 6 months. The whole duration of the study is 48 months.
Evaluation criteria: Audiological testing (pure-tone hearing thresholds, speech comprehension in quiet and noise), and subjective evaluation using self-assessment scales will be performed before and 6 months after the implantation in the two groups.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Olivier STERKERS, MD,PhD | +33(0) 1 40 87 56 29 | olivier.sterkers@bjn.aphp.fr |
France | |
Hopital de Bobigny | Recruiting |
BOBIGNY, France, 93009 | |
Contact: Olivier STERKERS, MD,PhD +33 (0) 1 40 87 56 29 olivier.sterkers@bjn.aphp.fr |
Principal Investigator: | Olivier STERKERS, MD,PhD | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Department Clinical Research of Developpement ( Cecile JOURDAIN ) |
Study ID Numbers: | P051023 |
Study First Received: | March 21, 2007 |
Last Updated: | April 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00451503 |
Health Authority: | France: Ministry of Health |
Hearing Auditory rehabilitation Middle ear implant Surgery |
Signs and Symptoms Sensation Disorders Hearing Disorders Deafness |
Otorhinolaryngologic Diseases Neurologic Manifestations Hearing Loss Ear Diseases |
Nervous System Diseases |